Aberrantly hypermethylated ARID1B is a novel biomarker and potential therapeutic target of colon adenocarcinoma

Aberrantly hypermethylated ARID1B is a novel biomarker and potential therapeutic target of colon adenocarcinoma

Background and Objective: Understanding the tumor microenvironment (TME) and immune cell infiltration (ICI) may help guide immunotherapy efforts for colon cancer (COAD). However, whether ARID1B is truly regulated by hypermethylation or linked to immune infiltration remains unknown. The current work...

Full description

Bibliographic Details
Main Authors: Salem Baldi, Yun He, Igor Ivanov, Hassan Khamgan, Mohammed Safi, Mohammed Alradhi, Abdullah Shopit, Abdullah Al-Danakh, Murad Al-Nusaif, Yaping Gao, Hui Tian
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Genetics
Subjects:
ARID1B
DNA Methylation
RNA expression
Immune Cell Infiltration
Colon adenocarcinoma
TCGA
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2022.914354/full

Internet

https://www.frontiersin.org/articles/10.3389/fgene.2022.914354/full

Similar Items